• Voluntarily sign the informed consent and follow the requirements of the protocol;

• No gender limit;

• Age: ≥18 years old and ≤75 years old (stage Ia); ≥18 years old (stage Ib);

• Expected survival time ≥3 months;

• Histologically and/or cytologically confirmed locally advanced or metastatic solid tumors that are incurable or currently have no standard treatment;

• Consent to provide archival tumor tissue samples or fresh tissue samples from primary or metastatic lesions within 2 years;

• Must have at least one measurable lesion according to RECIST v1.1 definition;

• ECOG 0 or 1;

• Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;

⁃ No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;

⁃ The level of organ function must meet the requirements on the premise that blood transfusion is not allowed within 14 days before the screening period and no cell growth factor drugs are allowed;

⁃ Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN;

⁃ The urine protein + 2 or 1000 mg / 24 h or less or less;

⁃ For premenopausal women with fertility may have to 7 days before beginning treatment for a pregnancy test, serum pregnancy must be negative, and must not be lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.